Medication info
Sitaro M Tablets 50/850 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride Colloidal Silicon Dioxide)

Sitaro M Tablets 50/850 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride Colloidal Silicon Dioxide)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200311 · Approved 2022.01.19 · Insurance code 645306910

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
  • difficulty in maintaining adequate blood sugar control
View approved original text

This medication is used to assist in blood sugar control in patients with type 2 diabetes along with dietary and exercise therapies. It can be administered as monotherapy to patients who are not currently receiving antidiabetic medication. It is also used when blood sugar control is difficult with either metformin or sitagliptin alone, or to replace the combined use of both medications. It is administered in conjunction with this medication when blood sugar control is insufficient with a combination of metformin and sulfonylurea or between metformin and thiazolidinedione. This medication is also used when the combination therapy of insulin and metformin is ineffective. In this way, it helps improve blood sugar control in various situations, thereby enhancing diabetes management for the patient.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Precautions

This medication may cause allergic reactions; therefore, if symptoms such as skin rash, hives, or difficulty breathing appear, you must immediately discontinue use and consult a physician. Additionally, there are rare reports of severe side effects such as pancreatitis, which is inflammation of the pancreas; if abdominal pain or vomiting occurs while taking this medicine, notify healthcare providers immediately. This medication should not be taken by patients with impaired kidney function or severe infections, heart failure, acute myocardial infarction, etc., and kidney function should be checked regularly. When undergoing imaging tests using radiographic contrast agents, this medication should be temporarily discontinued before and after the test, and it should be resumed only after confirming that kidney function is normal. Pregnant women or those who may become pregnant, as well as nursing mothers, should not take this medication for safety. While on this medication, it is necessary to be cautious as irregular eating, excessive exercise, and concomitant use of other blood sugar-lowering agents may lead to hypoglycemia. Due to the metformin component, rare but serious metabolic abnormalities such as lactic acidosis may occur, so if symptoms like fatigue, muscle pain, difficulty breathing, or abdominal pain occur, notify healthcare providers immediately. Alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid drinking while on it. If surgery is to be performed, this medication should be stopped 48 hours before surgery, and it can be resumed only after confirming the patient's condition is stable and kidney function is normal post-surgery. This medication may cause side effects such as gastrointestinal disturbances, headaches, and upper respiratory infections, and hypoglycemic symptoms may also occur; therefore, it is essential to consult a healthcare provider immediately if symptoms occur. Regular blood tests and kidney function tests are required, and especially in the elderly, careful monitoring is vital due to the higher risk of side effects related to decreased kidney function. In case of overdose of this medication, one must immediately visit a hospital for appropriate treatment, and some components may be removed through dialysis. If severe joint pain or blistering skin symptoms appear during treatment, you must immediately discontinue the medication and consult a specialist.

Side effects

anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, arthritis with severe symptoms and disability, blistering dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rash, urticaria, cutaneous vasculitis, elevated liver enzyme levels, acute renal failure, dyspnea, unstable angina, dizziness, decreased appetite, itching, constipation, gastrointestinal gas distension, abdominal discomfort, dyspepsia, asthenia, severe hypoglycemia, dermatitis, weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and should be kept at room temperature between 1 and 30 degrees Celsius for safety. Storing this way can help maintain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.